Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01561820
Other study ID # IRB00018495
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2011
Est. completion date December 2012

Study information

Verified date September 2019
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a small pilot trial of a 5 month aerobic exercise intervention in participants with MCI (n=20) to begin to compare the effects of randomization to use an exercise buddy or to exercise without an assigned buddy. The investigators hypothesize that participants with MCI who exercise with a buddy will have higher adherence to the protocol and greater improvement in 400 meter walk time.


Description:

The overall objective of this pilot study is to determine feasibility and gather data that will inform the design of a larger, multicenter, randomized, controlled trial. Specifically, the investigators aim to:

2.1 Determine the feasibility of recruiting persons with MCI and a buddy for an exercise intervention.

- For MCI participants who do not identify a buddy, the investigators will determine the interest and feasibility of recruiting volunteers from the community to be an exercise buddy.

2.2 Determine the effects of having an exercise buddy on:

- adherence to the protocol

- 400 meter walk time, an objective measure of improved physical fitness

- retention and satisfaction for both participant with MCI and buddy

2.3 Establish a scientific partnership with a community based exercise facility.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria:

Participants:

- Age 60 and up

- Montreal Cognitive Assessment (MoCA) score 16-28

- CDR= 0.5 with memory box at least 0.5.

- Have a person (study partner) who can answer questions about their cognition for the CDR, FAQ and NPI-Q. This should be the same person who will come to all clinic visits whenever possible. This person can be called to answer these questions if unable to come into the clinic.

- Sedentary for past 3 months (< 45 min /wk of exercise, including walking)

- Able to walk 400 meters in < 15 min without assistance

- Willing to exercise 4 days a week at Body Check at CompRehab

- Physician approval for participation in the exercise intervention

Buddy:

- No report of memory problem

- MoCA score > 24 if > HS education; > 23 if 9-12 years; > 22 if ,< 9 years of education

Exclusion Criteria:

Due to Cognitive Confounders:

- Uncontrolled depression (PHQ-9 > 10)

- Schizophrenia or bipolar disorder

- Parkinson's disease

- Hachinski ischemic index > 4

- Daily use of highly anticholinergic medications (such as amitriptyline, diphenhydramine, scopolamine, etc) or benzodiazepines

- Use of stable dose of Cholinesterase inhibitors will be permitted. Must be on a stable dose for 4 weeks.

- Non-English speaking (as we are unable to administer the cognitive tests in languages other than English for this pilot)

- Vitamin B12 deficiency

- Uncontrolled hypothyroidism as measured by TSH blood test

Due to increased risk of or low likelihood of compliance with the exercise program:

- Active ischemic heart disease or angina

- symptomatic heart failure

- stroke

- screening blood pressure SBP > 170 or < 90; DBP > 100 or < 45

- Parkinson's disease or other neurologic disorder that might make exercise on a treadmill or bike unsafe

- Current or planned treatment for cancer

- peripheral artery disease that limits exercise capacity

- Severe respiratory-disease (e.g., COPD) that limits exercise capacity

- Severe arthritis that limits exercise capacity

- Serious conduction disorder, uncontrolled arrhythmia, or new Q waves or ST-segment depressions (> 3 mm) on ECG

- Severe anemia (Hgb < 8)

- Diagnosis of Diabetes and on medication

- Drinks more than 14 alcoholic drinks per week

- Dependent on a cane, walker or other device that would inhibit then from using a treadmill

Study Design


Intervention

Behavioral:
5-month aerobic exercise intervention
The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5[HRmax-HRrest]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.

Locations

Country Name City State
United States Wake Forest Baptist Health Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adherence (number of sessions attended and exercise duration in targeted heart rate zone) This is a pilot study with the principle outcome measures related to recruitment and retention of participants with MCI and buddies and adherence to the protocol. We are specifically interested in:
Time to recruit 20 participants
% of participants who identify their own buddy
Number of community volunteers to be buddies over the recruitment period
Retention at 3- and 5- months
Adherence (number of exercise sessions attended, exercise duration in targeted HR zone)
4 times a week for 5 months (each exercise session)
Secondary Change in score on Digit Symbol Coding Test Baseline 3 months and 5 months
Secondary Change in 400m walk time (from randomization to 5 months) Baseline, 3 months and 5 months
Secondary Change in Trail Making Test part B score Baseline and 5 months
Secondary change in memory, measured by Rey AVLT delayed recall score, at 5 months baseline and 5 months
See also
  Status Clinical Trial Phase
Completed NCT04513106 - Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial N/A
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Active, not recruiting NCT03167840 - Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment N/A
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting NCT05041790 - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment Phase 4
Recruiting NCT04121156 - High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT02774083 - Cognitive Training Using Feuerstein Instrumental Enrichment N/A
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Enrolling by invitation NCT06023446 - Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A